<scp>DORA</scp>: 48‐week weight and metabolic changes in Black women with <scp>HIV</scp>, in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapy
Our findings suggest that a switch to doravirine from efavirenz or dolutegravir is safe and effective in Black women, with significant improvement in lipid profiles, but does not arrest progressive weight gain.
Authors
- Michelle Moorhouse (ORCID: https://orcid.org/0000-0002-8410-3247)
- Joana Woods (ORCID: https://orcid.org/0000-0003-3507-3800)
- Simiso Mandisa Sokhela (ORCID: https://orcid.org/0000-0002-2707-1533)
- François Venter (ORCID: https://orcid.org/0000-0002-4157-732X)
- Karlien Möller (ORCID: https://orcid.org/0000-0001-7665-4666)
- Bronwyn Bosch (ORCID: https://orcid.org/0000-0002-8060-4589)
- Andrew Hill (ORCID: https://orcid.org/0000-0002-2875-0546)
- Godspower Akpomiemie (ORCID: https://orcid.org/0000-0001-8982-1099)
- Esther Bhaskar
- Nomathemba Chandiwana (ORCID: https://orcid.org/0000-0001-7866-2651)
- Chelsea Kruger
- Ncomeka Manentsa
- Philadelphia Macholo
- Noxolo Tom
Institutions
- University of Liverpool (GB)
- University of the Witwatersrand (ZA)
- University of Pretoria (ZA)
Publication Details
- Journal
- HIV Medicine
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1111/hiv.13711
- Citations
- 4
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.76
Funders
- United States Agency for International Development
- Bill and Melinda Gates Foundation
- Gilead Sciences
- Children's Investment Fund Foundation
- ViiV Healthcare
- MSD K.K.
- Medical Research Council